MAZUR, Michał, WAZ, Dorota, SZARŁOWICZ, Jakub, GOLISZEK, Zofia, SOBEK, Karolina Łucja, TABIN-BARCZAK, Wiktoria, SOKOŁOWSKA, Aldona, FIKAS, Klaudia, CHWALISZEWSKI, Kamil and SAMUŁA, Sebastian. Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health. Quality in Sport. 2024;36:56722. eISSN 2450-3118.
https://doi.org/10.12775/QS.2024.36.56722
https://apcz.umk.pl/QS/article/view/56722

The journal has been 20 points in the Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.
Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.
Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 06.12.2024. Revised: 19.12.2024. Accepted: 20.12.2024. Published: 20.12.2024.

Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health

Michał Mazur,
University of Rzeszów
al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
https://orcid.org/0009-0007-3840-4325
michalmazur1998@gmail.com

Dorota Waz
Medical Center in Łańcut, Poland
Ignacego Paderewskiego 5, 37-100 Łańcut, Poland
https://orcid.org/0009-0004-7484-9231
dorota.waz1@gmail.com

Jakub Szarłowicz,
Medical Center in Łańcut, Poland
Ignacego Paderewskiego 5, 37-100 Łańcut, Poland
https://orcid.org/0009-0006-8520-9496
szarlowicz.jakub@gmail.com

Zofia Goliszek
Medical Center in Łańcut, Poland
Ignacego Paderewskiego 5, 37-100 Łańcut, Poland
https://orcid.org/0009-0005-9881-5754
goliszek1489@gmail.com

Karolina Łucja Sobek
Medical Center in Łańcut, Poland
Ignacego Paderewskiego 5, 37-100 Łańcut, Poland
https://orcid.org/0009-0000-2551-0515
karolinasobek46@gmail.com

Wiktoria Tabin-Barczak
University of Rzeszów
al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
https://orcid.org/0009-0003-8333-8428
wiktoria2509@gmail.com

Aldona Sokołowska
Provincial Clinical Hospital No. 2 named after saint Jadwiga the Queen in Rzeszów,
Lwowska 60, 35-301 Rzeszów
https://orcid.org/0009-0006-8723-2593
aldonasokolowskaa@gmail.com

Klaudia Fikas,
University of Rzeszów
al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
https://orcid.org/0009-0008-1976-2941
fikasklaudia9@gmail.com

Kamil Chwaliszewski,
University of Rzeszów
al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland
https://orcid.org/0009-0003-7239-3122
chwaliszewskikamil@gmail.com

Sebastian Samuła
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin,
Aleja Kraśnicka 100, 20-718 Lublin, Poland
https://orcid.org/0009-0008-8915-4263
sebastian.s94424@gmail.com

Corresponding author: Michał Mazur, michalmazur1998@gmail.com

Abstract

Introduction and Purpose:

T2DM is a metabolic condition with significant global health implications, largely driven by aging populations and the obesity epidemic. Glucagon-like peptide-1 receptor agonists have transformed T2DM treatment by offering benefits that extend beyond blood glucose control, including weight reduction, cardiovascular protection, and potential effects on related metabolic conditions. This review aims to explore the mechanisms of GLP-1 RAs, their clinical applications, and their evolving role in addressing T2DM and its associated complications.

Materials and Methods:

The review is based on a detailed analysis of peer-reviewed studies from major scientific databases such as PubMed. The selected literature focuses on the mechanisms, clinical benefits, and new developments in GLP-1 RA therapies, including innovations in drug formulations and combination treatments.

Results:

GLP-1 RAs enhance glycemic control by stimulating glucose-dependent insulin secretion and suppressing glucagon release, with a low risk of hypoglycemia. They also facilitate significant weight loss by regulating appetite and slowing gastric emptying. Beyond these core effects, GLP-1 RAs reduce cardiovascular risks, slow the progression of chronic kidney disease, and show promise in managing NAFLD and neuroinflammation. Innovations such as dual and triple agonists and oral GLP-1 RA formulations have further expanded their therapeutic scope, improving patient outcomes and adherence.

Conclusion:

GLP-1 RAs represent a significant advancement in the management of T2DM and related metabolic disorders. By addressing interconnected issues such as glycemic control, weight management, and cardiovascular risk, these therapies play a central role in modern metabolic medicine. Ongoing research should focus on long-term outcomes, safety, and personalized approaches to maximize their full potential and accessibility.

Keywords:

type 2 diabetes mellitus; GLP-1 receptor agonist; cardiovascular benefits; weight management; non-alcoholic fatty liver disease; tirzepatide; chronic kidney disease; personalised medicine.

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic and multifaceted metabolic disorder affecting over 11% of the U.S. population, with aging and obesity as its primary risk factors. Nearly 40% of individuals with T2DM are aged 65 or older, a demographic burdened by heightened risks of cardiovascular diseases, cancer, and other obesity-related complications often exacerbated by metabolic syndrome [1]. As the seventh leading cause of death in the United States, diabetes represents a significant public health challenge, underscoring the urgent need for innovative therapeutic strategies [2].

In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents in managing T2DM and obesity. These pharmacological agents mimic the incretin hormone GLP-1, secreted by intestinal L cells in response to nutrient intake, to regulate glucose homeostasis. Their mechanisms include glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and enhanced satiety [3]. These multifaceted effects extend well beyond glycemic control, facilitating significant weight loss and positioning GLP-1 RAs as a cornerstone in contemporary metabolic therapy [4].

The development of GLP-1 RAs has significantly advanced patient care through improved formulations and delivery options. Semaglutide, for instance, is available as both a weekly injectable and a daily oral preparation, offering versatility for individuals hesitant to begin injectable treatments [5]. Recent clinical trials such as PIONEER-PLUS have underscored the efficacy of higher doses of oral semaglutide (50 mg daily), which achieved

superior weight loss outcomes compared to lower doses, thereby broadening the utility and appeal of this drug class [6].

Beyond their primary role in glycemic management, GLP-1 RAs confer a range of systemic benefits, particularly in cardiovascular health. Robust clinical trials have shown reductions in major adverse cardiovascular events (MACE)—including myocardial infarction, stroke, and cardiovascular mortality—along with decreased risk of heart failure hospitalization. These cardiovascular benefits are complemented by renoprotective effects, such as reduced albuminuria and slower progression of chronic kidney disease, which occur independently of glycemic control [3][5]. Additionally, GLP-1 RAs have shown promise in mitigating non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis, expanding their potential utility in managing complex metabolic disorders [4][5].

The systemic actions of GLP-1 RAs are attributed to the widespread expression of GLP-1 receptors across multiple tissues, including the pancreas, central nervous system, liver, kidneys, and adipose tissue. This receptor distribution supports diverse physiological effects, such as enhancing insulin secretion, reducing inflammation, increasing energy expenditure, and improving cellular health [3][5]. Emerging preclinical studies suggest that GLP-1 RAs may also possess anti-aging properties by modulating oxidative stress, reducing cellular senescence, and promoting tissue homeostasis [4][5][7]. Furthermore, these agents have demonstrated the potential to address co-morbidities associated with obesity, such as cardiovascular disease and non-alcoholic steatohepatitis (NASH), positioning them as versatile tools in metabolic health management [7].

The evolving pharmacological landscape of GLP-1 RAs is further shaped by the advent of novel combination therapies, including dual and triple receptor agonists. Agents like tirzepatide, which combines GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonism, have shown unprecedented efficacy in achieving weight loss comparable to bariatric surgery, while improving insulin sensitivity and metabolic parameters [4][5][7]. Clinical trials such as SURMOUNT-1 have demonstrated that tirzepatide facilitates an average weight loss of up to 20.9% over 72 weeks, along with significant cardiovascular and renal benefits, heralding a new era in metabolic pharmacotherapy [5][7]. Similarly, emerging co-agonists targeting GLP-1, glucagon, and additional pathways are showing enhanced efficacy in early clinical evaluations, further extending the therapeutic potential of this drug class [7].

This review aims to provide a comprehensive exploration of GLP-1 RAs and related therapies, delving into their mechanisms of action, clinical efficacy, and expanding roles in managing T2DM, obesity, and other systemic conditions. As metabolic pharmacology continues to advance, GLP-1-based therapies represent a promising frontier, poised to reshape the treatment paradigms of diabetes and its complications while addressing the broader spectrum of metabolic health challenges.

Mechanisms of Action and Clinical Applications of GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a cornerstone in managing type 2 diabetes mellitus (T2DM) and obesity. Their unique ability to influence not only blood glucose levels but also weight, cardiovascular health, and overall metabolic function places them at the forefront of modern therapeutics.

Insights into the mechanisms of GLP-1, including its production, receptor distribution, and systemic effects, have broadened their utility in clinical practice [1][2][3][4].

Glycemic Control and Pancreatic Function

The primary therapeutic effect of GLP-1 RAs is their ability to modulate insulin and glucagon secretion in a glucose-dependent manner. By binding to GLP-1 receptors on pancreatic β-cells, these agents stimulate insulin release only when blood glucose levels are elevated, minimizing the risk of hypoglycemia that often accompanies traditional diabetes treatments [1][2]. Simultaneously, GLP-1 RAs suppress glucagon secretion from α-cells, thereby improving postprandial glucose control and lowering fasting glucose levels [3].

Additionally, GLP-1 RAs offer protective benefits for pancreatic β-cells by promoting their survival and encouraging cell regeneration, mechanisms critical for counteracting the progressive β-cell decline seen in T2DM [4][5]. Long-acting formulations such as dulaglutide and semaglutide are particularly effective, maintaining steady receptor activation and reducing glycated hemoglobin (HbA1c) levels by 1.0–1.5% in clinical trials [6]. These agents are often recommended for patients who fail to achieve glycemic targets with oral medications or those unable to tolerate first-line therapies like metformin [7].

Weight Regulation and Appetite Control

One of the standout features of GLP-1 RAs is their dual role in diabetes and weight management. These agents significantly reduce body weight, an outcome particularly beneficial for patients with obesity-related T2DM. Their weight-loss effects arise from actions on hypothalamic GLP-1 receptors, which regulate appetite and satiety [8]. These drugs enhance feelings of fullness, suppress hunger, and slow gastric emptying, collectively reducing caloric intake [9].

Among the various GLP-1 RAs, semaglutide has shown exceptional results, with average weight reductions exceeding 10% of baseline body weight in clinical studies [10]. The involvement of GLP-1-producing neurons in the brainstem, which contribute to appetite control, adds another dimension to their efficacy. However, the interplay between gut-derived and brain-derived GLP-1 remains an area of active research [9][10].

Cardiovascular and Renal Protection

GLP-1 RAs have demonstrated profound cardiovascular benefits, as evidenced by large clinical trials. These agents consistently lower the risk of major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death [8]. These effects are partly attributable to indirect mechanisms such as weight loss, better lipid profiles, and reduced blood pressure, alongside direct anti-inflammatory and atheroprotective actions [9].

Semaglutide and dulaglutide, in particular, stand out for their ability to reduce cardiovascular risk in patients with a history of atherosclerotic cardiovascular disease (ASCVD) or other significant risk factors [10]. Beyond the heart, GLP-1 RAs also benefit kidney health. They have been shown to slow the progression of chronic kidney disease (CKD) by reducing albuminuria and stabilizing renal function, outcomes that are especially significant for patients with diabetic kidney disease (DKD) [8][9].

Structural Variability and Pharmacokinetics

The distinct molecular structures and pharmacokinetics of GLP-1 RAs influence their clinical applications. Agents derived from the human GLP-1 backbone, like dulaglutide, have unique distribution profiles compared to those

based on exendin-4, such as exenatide. These differences impact receptor binding, activity duration, and overall efficacy [10].

Semaglutide, available in both injectable and oral formulations, represents a significant innovation. The oral version provides greater flexibility for patients who prefer to avoid injections, expanding access to this class of medication [9]. These advancements highlight the ongoing evolution of GLP-1 RAs and their expanding role in personalized treatment strategies.

Impact on Glycemic Control in Type 2 Diabetes Mellitus

Managing Type 2 Diabetes Mellitus (T2DM) requires effective strategies to achieve and maintain glycemic control, as this helps reduce both microvascular and macrovascular complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a prominent class of medications that have proven effective not only in lowering glycated hemoglobin (HbA1c) but also in providing additional benefits such as weight loss and cardiovascular protection.

Comparative Efficacy in Reducing HbA1c

GLP-1 RAs have been shown to significantly lower HbA1c levels, often achieving reductions between 1.0% and 1.8%. These results vary based on the specific drug, the dosage, and the patient's baseline HbA1c. Importantly, these agents often outperform older therapies, such as sulfonylureas or dipeptidyl peptidase-4 inhibitors (DPP-4is), in achieving glycemic targets. For example, long-acting GLP-1 RAs such as semaglutide and dulaglutide consistently demonstrate superior reductions in fasting glucose and overall HbA1c levels compared to their short-acting counterparts [1][6][11].

Moreover, studies emphasize the effectiveness of GLP-1 RAs when used as part of combination regimens. Combining these agents with other antidiabetic drugs, such as metformin or sodium-glucose cotransporter-2 inhibitors (SGLT-2is), enhances their glycemic-lowering effects. For example, GLP-1 RAs complement the action of SGLT-2is, as the former stimulates insulin secretion and suppresses glucagon while the latter reduces glucose reabsorption in the kidneys [11].

Sustained Glycemic Control with Different Formulations

GLP-1 RAs are available in both short-acting and long-acting formulations, allowing for flexibility based on individual patient needs. Long-acting agents, such as semaglutide and dulaglutide, maintain steady receptor activation, providing consistent glycemic control over an extended period. These medications are particularly beneficial for patients struggling with elevated fasting glucose levels or those requiring stable HbA1c management [6][11].

In contrast, short-acting GLP-1 RAs, such as exenatide, primarily target postprandial glucose spikes. These are often used in specific scenarios where managing meal-related glycemic excursions is a priority. However, their overall impact on HbA1c tends to be less pronounced compared to their long-acting counterparts. As a result, long-acting formulations have become the preferred choice for most patients with T2DM who require intensive glycemic management [6][11].

3.3 The Role of Combination Therapy

The incorporation of GLP-1 RAs into combination therapies has revolutionized diabetes care, particularly for individuals with suboptimal glycemic control on monotherapy. Combining GLP-1 RAs with metformin or SGLT-2is has proven to be an effective strategy for achieving tighter glycemic control. Research has demonstrated that these combinations often yield superior HbA1c reductions while providing added benefits such as weight loss and cardiovascular risk reduction [11][12].

One notable advancement in combination therapy is the introduction of dual agonists, such as tirzepatide, which simultaneously target GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This approach has resulted in unprecedented reductions in HbA1c—up to 2.1%—in patients previously uncontrolled on metformin monotherapy. The integration of such novel agents into clinical practice further underscores the potential of combination therapies to address the multifaceted challenges of T2DM management [12].

3.4 Advantages Beyond Glycemic Control

A key advantage of GLP-1 RAs lies in their ability to lower HbA1c without significantly increasing the risk of hypoglycemia. This is achieved through their glucose-dependent mechanism of action, which enhances insulin secretion only in the presence of hyperglycemia. Unlike traditional treatments such as sulfonylureas or insulin, GLP-1 RAs thus offer a safer profile for most patients [1][3][11].

In addition to glycemic benefits, GLP-1 Ras have many other positive effects for the human body (Figure 1). They are particularly effective in promoting weight loss. Clinical trials have demonstrated that semaglutide, for instance, can lead to reductions in body weight exceeding 10% of baseline weight in many patients. These weight-loss effects, coupled with the cardiovascular benefits consistently observed in clinical trials, make GLP-1 RAs an invaluable tool in managing T2DM, especially in individuals with obesity or a high risk of cardiovascular events [11].

Comprehensive Benefits and Considerations for GLP-1 Receptor Agonists

Figure 1. Representative targets for GLP-1 action and sites of GLP1R expression within the nervous system, and consequences of GLP-1 therapy in people with obesity [7]

Overview of GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are pivotal in the management of type 2 diabetes mellitus (T2DM). These agents function by enhancing glucose-dependent insulin secretion while suppressing inappropriate glucagon release, a dual mechanism that ensures effective glycemic control without significantly increasing the risk of hypoglycemia. However, their benefits extend far beyond glucose regulation. Recent studies highlight their roles in weight management, cardiovascular protection, and potentially even neuroprotection [1, 13, 14].

The versatility of GLP-1 RAs makes them suitable for addressing complex conditions such as metabolic syndrome and obesity. By promoting satiety and delaying gastric emptying, GLP-1 RAs contribute significantly to weight loss, which is particularly valuable for patients with comorbidities like hypertension and dyslipidemia. Furthermore, the emerging neuroprotective effects suggest that these agents may play a role in preventing or mitigating cognitive decline, a promising avenue for future research [13].

Cardiovascular Implications

Reduction of Cardiovascular Events

Multiple cardiovascular outcome trials (CVOTs) have demonstrated the efficacy of GLP-1 RAs in reducing major adverse cardiovascular events (MACE) among high-risk populations. For example, the LEADER trial revealed that liraglutide reduced MACE by 13%, while the SUSTAIN-6 trial showed that semaglutide lowered the incidence of MACE by 26%, driven primarily by a significant reduction in nonfatal stroke risk [13]. These results underline the essential role of GLP-1 RAs in cardiovascular risk management, making them a critical choice for patients with diabetes and established cardiovascular disease or multiple risk factors.

Renal and Endothelial Benefits

Beyond cardiovascular protection, GLP-1 RAs offer additional benefits for renal and vascular health. They have been shown to reduce albuminuria, a marker of kidney damage, and decrease oxidative stress in renal tissues, which collectively contribute to their renoprotective properties. Simultaneously, these agents improve endothelial

function by enhancing nitric oxide availability, leading to better vascular compliance and reduced blood pressure levels. These combined effects contribute significantly to the reduction of vascular disease burden in diabetic patients [14, 15].

GLP-1 Receptor Agonists in Pregnancy

Reproductive Safety

The safety of GLP-1 RAs during pregnancy, particularly in the first trimester, has been a subject of increasing interest. Findings from a multicenter observational cohort study indicate that inadvertent exposure to GLP-1 RAs during early pregnancy is not associated with an elevated risk of major congenital anomalies. The rates of birth defects in GLP-1 RA-exposed pregnancies were 2.6%, closely mirroring those observed in women with diabetes treated with non-GLP-1 RA antidiabetic medications (2.3%) and slightly lower than in overweight/obese women without diabetes (3.9%) [16].

Pregnancy Outcomes

Pregnancies involving GLP-1 RA exposure did not show a significant increase in the rates of pregnancy losses compared to reference groups. The incidences of live births, pregnancy losses, and elective terminations were comparable across cohorts. However, the GLP-1 RA group exhibited a higher rate of elective terminations, likely reflecting patient and provider concerns regarding fetal safety. This underscores the need for clear clinical guidelines and effective counseling to reassure patients and mitigate undue anxiety [16].

Implications for Weight Management in Women of Reproductive Age

Given the growing prevalence of obesity among women of childbearing age, the increasing use of GLP-1 RAs for weight management is noteworthy. In one study, 70% of women receiving GLP-1 RAs used them primarily for weight loss. This trend highlights the importance of understanding the reproductive safety of these agents, particularly as nearly half of pregnancies worldwide are unplanned [16]. Healthcare providers must weigh the metabolic benefits of GLP-1 RAs against the potential risks during pregnancy, emphasizing the need for comprehensive preconception counseling and careful patient selection.

Neurological and Stress Responses

Role of GLP-1 in Stress Modulation

The central nervous system (CNS) effects of GLP-1 are increasingly recognized, particularly in the context of stress modulation. GLP-1-producing neurons located in the caudal nucleus of the solitary tract (cNTS) integrate signals of energy balance and stress. These neurons project to brain regions such as the hypothalamus and amygdala, where they activate GLP-1 receptors, mediating adaptive responses to stress. These responses include increased vigilance, activation of the sympathetic nervous system, and behavioral changes such as avoidance [15]. This central role positions GLP-1 as a potential target for therapeutic interventions in stress-related conditions.

Gut-Brain Neural Pathways

Recent findings reveal a complex gut-brain circuitry mediated by GLP-1. Intestinal L cells secrete GLP-1, which acts locally to inhibit gastric motility and suppress appetite. This effect is mediated through intestinofugal neurons, a specialized subset of myenteric neurons that transmit signals to abdominal sympathetic ganglia. These neurons, in turn, relay gastric distension signals to hypothalamic centers, orchestrating systemic responses such as appetite suppression and energy balance regulation [17]. Understanding this pathway highlights the potential of GLP-1 RAs in treating disorders that involve gut-brain axis dysregulation, such as gastroparesis and irritable bowel syndrome.

Chronic Stress and Neuroprotection

Chronic stress has been shown to downregulate GLP-1 expression, contributing to maladaptive responses that exacerbate anxiety and impair neuronal function. Preclinical studies suggest that GLP-1 RAs can counteract these effects by mitigating anxiety-like behaviors and preserving neuronal integrity under conditions of chronic stress. These findings support the therapeutic potential of GLP-1 RAs in managing stress-related disorders and enhancing overall neurological resilience [15].

Innovations and Future Directions

Dual and Triple Agonists

The development of dual GLP-1/GIP receptor agonists, such as tirzepatide, and triple agonists incorporating glucagon receptor activity represents a significant leap forward in diabetes and metabolic care. These novel agents promise superior glycemic control, greater weight reduction, and broader cardiometabolic benefits compared to GLP-1 RAs alone. By targeting multiple pathways, they address the interconnected nature of metabolic and cardiovascular diseases [14, 15, 17].

Personalized Approaches

As the therapeutic use of GLP-1 RAs expands to include non-diabetic individuals with high metabolic or cardiovascular risk, personalized treatment strategies are becoming increasingly important. Factors such as reproductive plans, comorbidities, and stress profiles must be carefully considered to optimize outcomes. Tailoring therapy to individual patient needs will enhance the effectiveness of GLP-1 RAs, ensuring their safe and successful integration into broader patient populations [13, 16, 17].

Safety and Adverse Effects of GLP-1 Receptor Agonists

General Safety Overview

GLP-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment landscape for type 2 diabetes (T2D) and obesity. By leveraging their glucose-dependent mechanisms, these medications offer effective glycemic control while minimizing the risk of hypoglycemia [1, 13]. However, like any pharmacological intervention, GLP-1 RAs are not without side effects. Among these, gastrointestinal (GI) issues are the most commonly reported and can impact patient adherence to treatment [18, 19]. Understanding these effects and implementing strategies to manage them is crucial for ensuring the effectiveness of therapy.

Gastrointestinal Adverse Events

Common Symptoms

The most frequent side effects associated with GLP-1 RAs are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. These issues affect 40–70% of patients in clinical trials [19]. They are often transient, typically occurring during the initial dose-escalation phase. As treatment continues and the maintenance dose is achieved, these symptoms generally decrease in severity, with most being mild to moderate [18, 19].

- **Nausea and Vomiting**: Nausea is the most commonly reported GI side effect, with incidence rates ranging from 15% to 50% in clinical studies [18]. Vomiting is less frequent, reported in 5–20% of cases [19]. These effects are believed to stem from delayed gastric emptying, a mechanism that also contributes to the appetite-suppressing benefits of GLP-1 RAs [17]. Symptoms usually resolve within a week.
- **Diarrhea and Constipation**: Diarrhea is reported in about 5–25% of patients, particularly in the early stages of treatment [18]. Constipation, affecting 4–12% of individuals, may persist longer, sometimes lasting for several weeks [19].

Management Strategies

Effectively managing GI side effects is key to maintaining treatment adherence. Strategies include:

1. **Gradual Dose Titration**: Initiating therapy at a low dose and slowly increasing it can help mitigate the intensity of side effects [19].
2. **Patient Education**: Advising patients on dietary adjustments, such as eating smaller meals and avoiding high-fat or spicy foods, can help reduce symptoms [19].
3. **Pharmacological Support**: For persistent nausea or vomiting, antiemetics like domperidone or prokinetic agents may be used [19]. Diarrhea can be managed with loperamide or probiotics, while fiber supplements and stool softeners may alleviate constipation [18, 19].
4. **Temporary Dose Adjustments**: Temporarily lowering the dose or extending the time between dose escalations can allow patients to build tolerance to the medication [18, 19].

Long-Term Safety Concerns

Pancreatobiliary Complications

Although infrequent, pancreatitis and gallbladder-related issues have been reported in association with GLP-1 RAs. The incidence of pancreatitis is below 1% in major trials, while gallstone formation and cholelithiasis are slightly more common, particularly in patients undergoing rapid weight loss, which can alter bile composition [19].

Management considerations include:

- Regular monitoring of individuals with a history of pancreatitis or gallbladder disease.
- Administering ursodeoxycholic acid for patients at high risk of gallstone formation [18, 19].

Cardiovascular and Renal Considerations

GLP-1 RAs have demonstrated notable benefits in reducing major adverse cardiovascular events (MACE) and improving renal outcomes. However, these medications may cause minor increases in heart rate, which are generally not clinically significant [13, 14, 19]. Careful monitoring is recommended for patients with pre-existing cardiovascular or renal conditions.

Safety in Specific Populations

Elderly Patients

Older adults often benefit significantly from the cardiovascular and renal protective effects of GLP-1 RAs. However, caution is needed for those aged 75 years and older to prevent unintended weight loss or muscle loss (sarcopenia) [18]. Nutritional counseling and individualized maintenance doses may be necessary to address these concerns [19].

Pregnancy

Although GLP-1 RAs are not typically recommended during pregnancy, accidental exposure has not been linked to increased risks of birth defects or pregnancy losses. Studies indicate comparable outcomes between exposed and unexposed groups [16]. These findings underscore the importance of counseling women of childbearing age who are considering or currently using GLP-1 RAs.

Patients with Gastrointestinal Disorders

Patients with mild to moderate GI conditions, such as gastroesophageal reflux disease (GERD) or chronic gastritis, generally tolerate GLP-1 RAs well. However, for individuals with severe gastrointestinal issues, limited data necessitate cautious use [19].

Patient Education and Support

Educating patients plays a pivotal role in ensuring the success of GLP-1 RA therapy. Key elements include:

- Setting realistic expectations about the transient nature of side effects.
- Offering clear dietary guidelines to minimize GI symptoms.
- Providing practical advice on symptom management, including the use of over-the-counter remedies and knowing when to consult a healthcare provider.

Innovations and Future Directions

Emerging Therapies

New agents like tirzepatide, which combines GLP-1 and GIP receptor agonism, have shown improved outcomes in glycemic control and weight management compared to standard GLP-1 RAs. However, these advancements come with similar GI side effects, especially at higher doses [18].

Personalized Treatment Approaches

Tailoring therapy to individual patient needs—considering factors such as age, comorbidities, and prior experiences with medications—can help optimize both efficacy and tolerability [19].

Current Trends and Future Directions in GLP-1 Receptor Agonist Research

Expanding the Applications of GLP-1 RAs: From Diabetes to Metabolic Syndrome

The evolution of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) from glucose-lowering agents to multifaceted therapies highlights their remarkable therapeutic potential. Originally designed for managing type 2 diabetes (T2D), GLP-1 RAs have demonstrated significant benefits beyond glycemic control, notably in addressing obesity, non-alcoholic fatty liver disease (NAFLD), and cardiovascular complications. These advancements reflect a growing understanding of the broader metabolic impacts of GLP-1 signaling.

Dual and Triple Agonist Approaches: Synergistic Mechanisms

Emerging therapies that combine GLP-1 receptor agonism with other hormonal pathways are at the forefront of current research. Dual agonists, such as tirzepatide, which target both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, have shown superior efficacy in weight reduction compared to traditional GLP-1 RAs. Clinical trials, such as the SURMOUNT series, have demonstrated weight loss of over 20% in participants, representing a significant leap in obesity management.

Similarly, triple agonists, combining GLP-1, GIP, and glucagon receptor agonism, offer a promising avenue. These therapies aim to harness the complementary actions of these hormones on appetite regulation, energy expenditure, and glucose metabolism. Preliminary studies in animal models and early-phase human trials suggest enhanced metabolic outcomes, including greater reductions in body weight and improved liver health metrics, compared to dual or single agonist therapies.

Innovations in Drug Delivery: Oral and Small-Molecule GLP-1 RAs

Traditionally, GLP-1 RAs have been administered via subcutaneous injection, posing challenges for patient adherence. Recent advancements include the development of oral GLP-1 RAs, such as oral semaglutide, which utilize innovative formulations to enhance gastrointestinal absorption. Additionally, small-molecule GLP-1 RAs like danuglipron are under investigation, potentially offering more convenient, non-peptide-based options for long-term therapy.

Applications Beyond Diabetes and Obesity

GLP-1 RAs are being explored for their potential role in treating conditions beyond T2D and obesity. For example, ongoing research is investigating their use in managing NAFLD and its progressive form, non-alcoholic steatohepatitis (NASH). By reducing hepatic steatosis, inflammation, and potentially fibrosis, GLP-1 RAs could emerge as a pivotal therapy for liver diseases linked to metabolic dysfunction.

Moreover, their neuroprotective effects are being examined in the context of neurodegenerative diseases like Alzheimer's. Preclinical data suggest that GLP-1 signaling might reduce neuroinflammation and oxidative stress, highlighting its potential as a therapeutic strategy for cognitive disorders.

Personalized Medicine: Tailoring GLP-1 RA Therapy

The variability in individual responses to GLP-1 RAs underscores the need for personalized treatment approaches. Biomarkers predicting therapeutic efficacy in glycemic control, weight loss, or cardiovascular protection are being actively researched. Additionally, genetic and phenotypic profiling could help optimize dosing strategies, minimize adverse effects, and improve long-term adherence.

Combining GLP-1 RAs with Other Therapies

The combination of GLP-1 RAs with other therapeutic classes, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors or amylin analogs, offers a synergistic approach to managing complex metabolic disorders. For instance, cagrilintide, an amylin analog combined with semaglutide, has shown enhanced weight reduction in clinical trials. These combinations address multiple pathways, offering comprehensive solutions for metabolic syndrome.

Future Challenges and Research Directions

Despite their promising applications, several challenges remain in GLP-1 RA therapy. Gastrointestinal side effects, such as nausea and diarrhea, continue to impact patient tolerance, especially during dose escalation. Strategies to mitigate these effects, including slower titration schedules and the development of agents with fewer side effects, are essential.

Long-term studies evaluating the impact of GLP-1 RAs on fibrosis regression in liver disease, sustained cardiovascular outcomes, and cancer risk are necessary to confirm their safety and efficacy. Additionally, cost considerations and accessibility issues must be addressed to ensure broader patient access to these innovative therapies.

Concluding Thoughts on the Horizon of GLP-1 RA Research

The advancements in GLP-1 RA research mark a transformative period in metabolic medicine. As dual and triple agonists progress through clinical trials, and as new delivery methods improve patient convenience, these therapies are poised to redefine the management of metabolic disorders. With their expanding indications and potential for combination therapies, GLP-1 RAs represent a cornerstone of future precision medicine approaches.

Conclusion

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have fundamentally transformed the treatment landscape for type 2 diabetes and obesity. These therapies have redefined clinical goals by offering exceptional glycemic control alongside substantial benefits in weight management, cardiovascular protection, and the mitigation of complications such as chronic kidney disease and non-alcoholic fatty liver disease. Their unique ability to address multiple aspects of metabolic dysfunction underscores their pivotal role in modern medical practice.

The development of newer GLP-1-based therapies, including dual and triple receptor agonists, as well as advancements in drug delivery methods like oral formulations, is expanding treatment possibilities. These innovations are poised to make therapy more effective and accessible, providing improved outcomes for patients with complex and multifaceted metabolic conditions.

While the benefits of GLP-1 RAs are clear, challenges remain, particularly in managing gastrointestinal side effects and ensuring equitable access for all patients. Moving forward, the emphasis will need to shift toward personalized

treatment approaches, tailoring therapy to meet the unique needs of individual patients. Additionally, long-term studies are crucial to understanding the broader impacts of these therapies on outcomes such as liver disease progression, neurodegeneration, and overall health.

In summary, GLP-1 RAs represent more than just a breakthrough in pharmacology; they embody a holistic approach to managing the interconnected challenges of metabolic disease. By improving health outcomes and quality of life for millions, these therapies pave the way for a future where personalized medicine and comprehensive metabolic care become the standard of treatment. The journey ahead for GLP-1 therapies is promising, and their potential continues to inspire advancements in both research and clinical care.

Disclosures

Author's contribution

Conceptualization – Michał Mazur, Dorota Waz, Zofia Goliszek

Formal analysis – Michał Mazur, Jakub Szarłowicz, Karolina Sobek

Investigation – Sebastian Samuła, Wiktoria Tabin-Barczak, Kamil Chwaliszewski

Data curation – Jakub Szarłowicz, Wiktoria Tabin-Barczak, Sebastian Samuła

Writing – rough preparation – Michał Mazur, Zofia Goliszek, Aldona Sokołowska

Writing – review and editing – Dorota Waz, Klaudia Fikas, Kamil Chwaliszewski

Visualization – Aldona Sokołowska, Klaudia Fikas, Karolina Sobek

All authors have read and agreed with published version of the manuscript.

Funding Statement – No applicable.

Institutional Review Board Statement – Not applicable.

Informed Consent Statement – Not applicable.

Data Availability Statement – The authors confirm that the data supporting this study are available in the article's references.

Conflict of Interest – Authors declare no conflict of interest.

References:

1. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. 2021;9(10):653-662. doi:10.1016/S2213-8587(21)00203-5

2. Ng E, Shaw JE, Wood A, Maple-Brown LJ, Hare MJ. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes. *Aust J Gen Pract*. 2022;51(7):513-518. doi:10.31128/AJGP-07-21-6057
3. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. *Mol Metab*. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
4. Wilbon SS, Kolonin MG. GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes. *Cells*. 2023;13(1):65. Published 2023 Dec 28. doi:10.3390/cells13010065
5. Melson E, Miras AD, Papamargaritis D. Future therapies for obesity. *Clin Med (Lond)*. 2023;23(4):337-346. doi:10.7861/clinmed.2023-0144
6. Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. *Front Endocrinol (Lausanne)*. 2021;12:721135. Published 2021 Aug 23. doi:10.3389/fendo.2021.721135
7. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. *Mol Metab*. 2022;57:101351. doi:10.1016/j.molmet.2021.101351
8. Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. *J Clin Pharm Ther*. 2020;45 Suppl 1(Suppl 1):17-27. doi:10.1111/jcpt.13230
9. Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; February 29, 2024.
10. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. *Endocr Rev*. 2021;42(2):101-132. doi:10.1210/endrev/bnaa032
11. Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. *J Clin Invest*. 2021;131(2):e142243. doi:10.1172/JCI142243
12. Weinberg Sibony R, Segev O, Dor S, Raz I. Drug Therapies for Diabetes. *Int J Mol Sci*. 2023;24(24):17147. Published 2023 Dec 5. doi:10.3390/ijms242417147
13. Ferhatbegović L, Mršić D, Macić-Džanković A. The benefits of GLP1 receptors in cardiovascular diseases. *Front Clin Diabetes Healthc*. 2023;4:1293926. Published 2023 Dec 8. doi:10.3389/fcdhc.2023.1293926
14. Myasoedova VA, Bozzi M, Valerio V, et al. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists. *Antioxidants (Basel)*. 2023;13(1):16. Published 2023 Dec 20. doi:10.3390/antiox13010016
15. Holt MK. Mind affects matter: Hindbrain GLP1 neurons link stress, physiology and behaviour. *Exp Physiol*. 2021;106(9):1853-1862. doi:10.1113/EP089445
16. Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. *BMJ Open*. 2024;14(4):e083550. Published 2024 Apr 24. doi:10.1136/bmjopen-2023-083550
17. Zhang T, Perkins MH, Chang H, Han W, de Araujo IE. An inter-organ neural circuit for appetite suppression. *Cell*. 2022;185(14):2478-2494.e28. doi:10.1016/j.cell.2022.05.007
18. Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. *Diabetologia*. 2022;65(8):1251-1261. doi:10.1007/s00125-022-05715-4
19. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. *J Clin Med*. 2022;12(1):145. Published 2022 Dec 24. doi:10.3390/jcm12010145
20. Nevola R, Epifani R, Imbriani S, et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. *Int J Mol Sci*. 2023;24(2):1703. Published 2023 Jan 15. doi:10.3390/ijms24021703
21. Jastreboff AM, Kushner RF. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. *Annu Rev Med*. 2023;74:125-139. doi:10.1146/annurev-med-043021-014919